These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16014756)

  • 21. Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.
    Ooi EM; Ng TW; Watts GF; Chan DC; Barrett PH
    J Lipid Res; 2012 Nov; 53(11):2443-9. PubMed ID: 22930812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.
    Hsu HC; Lee YT; Yeh HT; Chen MF
    J Lab Clin Med; 2001 Jun; 137(6):414-21. PubMed ID: 11385362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
    Pérez-Méndez O; Duhal N; Lacroix B; Bonte JP; Fruchart JC; Luc G
    Clin Chim Acta; 2006 Jun; 368(1-2):149-54. PubMed ID: 16487502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
    Parhofer KG; Barrett PH; Schwandt P
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4224-30. PubMed ID: 11095458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin.
    Maguire JJ; Wiley KE; Kuc RE; Stoneman VE; Bennett MR; Davenport AP
    Exp Biol Med (Maywood); 2006 Jun; 231(6):806-12. PubMed ID: 16741003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of very-low-density lipoprotein apolipoprotein B-100 in normolipidemic subjects: pooled analysis of stable-isotope studies.
    Watts GF; Moroz P; Barrett PH
    Metabolism; 2000 Sep; 49(9):1204-10. PubMed ID: 11016905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus.
    Tan KC; Shiu SW; Wong Y; Wong WK; Tam S
    Diabetes Metab Res Rev; 2006; 22(4):307-12. PubMed ID: 16389649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
    Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V
    Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
    Hogue JC; Lamarche B; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Mar; 57(3):380-6. PubMed ID: 18249211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of prebeta1 HDL and alphaHDL in type II diabetic patients.
    Chétiveaux M; Lalanne F; Lambert G; Zair Y; Ouguerram K; Krempf M
    Eur J Clin Invest; 2006 Jan; 36(1):29-34. PubMed ID: 16403007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
    Bilz S; Wagner S; Schmitz M; Bedynek A; Keller U; Demant T
    J Lipid Res; 2004 Jan; 45(1):174-85. PubMed ID: 14523053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
    Soedamah-Muthu SS; Colhoun HM; Thomason MJ; Betteridge DJ; Durrington PN; Hitman GA; Fuller JH; Julier K; Mackness MI; Neil HA;
    Atherosclerosis; 2003 Apr; 167(2):243-55. PubMed ID: 12818407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
    Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G
    Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit.
    Rashid S; Uffelman KD; Barrett PH; Lewis GF
    Circulation; 2002 Dec; 106(23):2955-60. PubMed ID: 12460878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
    Guerin M; Le Goff W; Duchene E; Julia Z; Nguyen T; Thuren T; Shear CL; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):148-54. PubMed ID: 17951324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.